Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efeito da Dieta Mediterrânica Modificada de Baixo Teor de Histamina na Esclerose Múltipla (HistaMed-MS)

14 de novembro de 2026 atualizado por: Murat Açık, Firat University

Um Ensaio Controlado Randomizado de uma Dieta Mediterrânica Modificada com Baixo Teor de Histamina na Esclerose Múltipla: O Efeito das Intervenções Dietéticas nos Achados Clínicos, Histamina Plasmática e Stress Oxidativo

This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS). The study will compare three groups: a low-histamine modified Mediterranean diet, a traditional Mediterranean diet, and a control group without dietary intervention. The main outcomes include clinical measures such as disability status, fatigue, and quality of life, as well as blood markers including plasma histamine, diamine oxidase concentration, total antioxidant capacity, and oxidative stress indicators. The goal is to determine whether reducing dietary histamine within a Mediterranean diet pattern provides additional benefits beyond a traditional Mediterranean diet in improving symptoms and biological markers related to inflammation and oxidative stress in RRMS.

Visão geral do estudo

Descrição detalhada

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Current immunomodulatory treatments have important side effects and do not fully address symptoms or quality of life, highlighting the need for complementary strategies such as targeted dietary interventions. The Mediterranean diet is one of the most promising patterns because of its anti-inflammatory and antioxidant properties and has been associated with reduced fatigue, improved quality of life, and potential benefits on disability in people with MS. However, some components of the traditional Mediterranean diet, such as certain fish, aged cheeses, fermented products, tomatoes, and citrus fruits, are relatively high in histamine. Histamine is a biogenic amine that may influence neuroinflammation and blood-brain barrier permeability, and diets that lower histamine intake have shown benefits in conditions like migraine and gastrointestinal dysfunction, which are common in MS. This study was designed to explore whether a low histamine-based modified Mediterranean diet can optimize the benefits of the Mediterranean pattern in relapsing-remitting MS (RRMS).

The trial is a three-arm, parallel-group, randomized controlled clinical study in adults with RRMS. Participants are randomly assigned to one of three groups: (1) a low histamine-based modified Mediterranean diet, which maintains the core principles of the Mediterranean pattern while restricting foods known to be high in histamine or to promote histamine release; (2) a traditional Mediterranean diet without specific histamine-related restrictions; or (3) a control group that does not receive a structured dietary intervention. The intervention focuses on high intake of fresh vegetables and fruits, legumes, whole grains, olive oil, and appropriate fish options, while the modified diet group additionally limits aged cheeses, processed meats, fermented foods, vinegar, fish and seafood, and selected vegetables and fruits that are high in histamine. This design allows direct comparison of no diet intervention, a well-established Mediterranean pattern, and a targeted low-histamine modification of that pattern.

Clinical outcomes include disability status assessed by the Expanded Disability Status Scale (EDSS), fatigue measured with the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), and health-related quality of life evaluated with the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. To investigate potential mechanisms, blood biomarkers are measured, including serum total antioxidant capacity, oxidative stress markers (for example malondialdehyde), plasma histamine levels, and plasma concentration of diamine oxidase (DAO), an enzyme that metabolizes histamine. The primary hypotheses are that both Mediterranean diet interventions will improve fatigue, quality of life, and oxidative stress parameters compared with the control group, and that the low histamine-based modified Mediterranean diet will provide the greatest benefits, particularly in reducing plasma histamine, increasing DAO concentration, and alleviating fatigue and disability scores in RRMS. If confirmed, the findings could support a more targeted dietary approach as a complementary medical nutrition therapy for MS and provide a basis for future interventional studies on histamine metabolism, oxidative stress, and diet in this population.

Tipo de estudo

Intervencional

Inscrição (Real)

57

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Elâzığ
      • Elâzığ, Elâzığ, Turquia (Türkiye), 23119
        • Firat University Hospital, Neurology Clinic

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos a 64 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 19 to 64 years.
  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to 2017 McDonald criteria.
  • EDSS score < 4.5.
  • On stable immunomodulatory treatment for at least 6 months.
  • Body mass index (BMI) 18.5-29.9 kg/m².

Exclusion Criteria:

  • Relapse and/or corticosteroid treatment within the last 1 month.
  • Clinically significant metabolic, progressive, or malignant disease.
  • Use of at least 1 g/day fish oil supplementation.
  • Insulin-dependent diabetes mellitus.
  • Participation in another interventional study.
  • Weight loss or gain ≥ 5% in the last 6 months.
  • Following a weight-loss diet in the last 2 months.
  • Use of oral anticoagulant therapy.
  • Presence of eating disorders, alcohol or substance dependence.
  • Pregnancy or breastfeeding.
  • Inability to comply with dietary intervention according to weekly follow-up assessments.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Low Histamine-Based Modified Mediterranean Diet

Participants receive a low histamine-based modified Mediterranean diet with restriction of high-histamine and histamine-releasing foods while preserving core Mediterranean diet principles.

Structured dietary program based on the Mediterranean diet with restriction of high-histamine and histamine-releasing foods (e.g., aged cheeses, processed meats, fish and seafood, fermented products, vinegar, some fruits and vegetables); fish is replaced with poultry.

Comparador Ativo: Traditional Mediterranean Diet

Participants receive a traditional Mediterranean diet without specific histamine-related restrictions.

Structured dietary program following a traditional Mediterranean diet rich in vegetables, fruits, whole grains, legumes, olive oil, and fish, without specific histamine-related restrictions.

Sem intervenção: Control (Usual Diet)

Participants continue their usual diet and do not receive a structured dietary intervention.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in neurological fatigue (Neurological Fatigue Index for Multiple Sclerosis [NFI-MS] subscale scores; ranges: physical fatigue 0-24, cognitive fatigue 0-12, diurnal sleep 0-18, nocturnal sleep 0-15; higher scores indicate greater fatigue)
Prazo: Baseline, week 6 and week 12

Fatigue will be assessed using the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), a 23-item self-reported questionnaire with four subscales: physical fatigue (8 items), cognitive fatigue (4 items), relief by diurnal sleep or rest (6 items), and abnormal nocturnal sleep and sleepiness (5 items). Items are rated from 0 to 3, each subscale is scored separately (no total score is calculated), and higher scores indicate greater fatigue. The outcome is the change in each subscale score from baseline to week 12 across the three study groups.

Baseline, week 6 and week 12
Change in plasma histamine concentration
Prazo: From baseline to 12 weeks

Plasma histamine will be measured in fasting EDTA plasma by competitive ELISA. The outcome is the change in plasma histamine concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks
Change in plasma diamine oxidase (DAO) concentration
Prazo: From baseline to 12 weeks

Plasma diamine oxidase (DAO), a key enzyme of histamine metabolism, will be measured in fasting EDTA plasma by sandwich ELISA. The outcome is the change in plasma DAO concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in disability status (Expanded Disability Status Scale [EDSS]; scale range: 0-10; higher scores indicate greater disability)
Prazo: From baseline to 12 weeks

Disability will be assessed using the Expanded Disability Status Scale (EDSS). The outcome is the change in EDSS score from baseline to the end of the intervention.

From baseline to 12 weeks
Change in health-related quality of life (Multiple Sclerosis Quality of Life-54 [MSQOL-54]; scale range: 0-100 for subscale and composite scores; higher scores indicate better health-related quality of life)
Prazo: From baseline to 12 weeks

Health-related quality of life will be assessed using the MSQOL-54 questionnaire. The outcome is the change in MSQOL-54 scores from baseline to the end of the intervention.

From baseline to 12 weeks
Change in serum total antioxidant capacity
Prazo: From baseline to 12 weeks

Serum total antioxidant capacity will be measured to evaluate antioxidant status. The outcome is the change in serum total antioxidant capacity between baseline and the end of the intervention.

From baseline to 12 weeks
Change in oxidative stress markers (e.g., malondialdehyde)
Prazo: From baseline to 12 weeks

Oxidative stress will be assessed using markers such as malondialdehyde (MDA). The outcome is the change in oxidative stress markers between baseline and the end of the intervention.

From baseline to 12 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Murat Gönen, Prof. Dr., Firat University Faculty of Medicine

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de junho de 2024

Conclusão Primária (Real)

10 de março de 2025

Conclusão do estudo (Real)

10 de junho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

22 de janeiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de março de 2026

Primeira postagem (Real)

30 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data underlying the results reported in the publication will be shared, together with the data dictionary.

Prazo de Compartilhamento de IPD

Beginning after publication of the main results.

Critérios de acesso de compartilhamento IPD

Available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

Tipo de informação de suporte de compartilhamento de IPD

  • ANALYTIC_CODE

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever